Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.